Recent News

  • UB Chemistry and Oncology Join Forces to Combat Kidney Cancer
    9/16/24
    Dr. Roberto Pili, MD (Hematology/Oncology) and Dr. David Heppner, PhD (Chemistry) have teamed up to develop treatments against an aggressive form of kidney cancer. The project has been awarded a five-year $1.8M NIH R01 National Cancer Institute R01 shared between the collaborating labs to advance drug discovery in a cancer type where limited therapeutic options are available. Read more about this collaborative work.
  • Prof. De Jesús Báez awarded Diversity & Inclusion Award
    9/13/24
    The American Physical Society (APS) has awarded Dr. Luis De Jesús Báez the 2024 FECS Diversity & Inclusion Award for his work to support and create opportunities for students from underrepresented backgrounds. This award represents efforts by Dr. De Jesús Báez from his postdoctoral and independent career, such as initiating a program connecting students from the University of Puerto Rico Cayey to REU and graduate opportunities at Texas A&M University.
  • FDA approval of a chemo-free lung cancer drug characterized by the Heppner Lab
    9/3/24
    A study published two years ago by Prof. David Heppner reported the first three-dimensional structures of Lazcluze (Lazertinib). The FDA recently approved this drug administered in combination with Rybrevant (Amivantamab) for the treatment of lung cancer.
  • Prof. Diana Aga listed a part of the Impactful 2024 Power List by The Analytical Scientist
    9/3/24
    The Analytical Scientist has included Prof. Aga in their 2024 impact list as a recognition of the Aga group’s impactful work at the forefront of planet protecting research, such emerging contaminants like PFAS. Read more in this article in The Analytical Scientist.